 |
|
Long-Term Efficacy of Mirabegron Add-On Therapy to Antimuscarinic Agents in Patients With Spinal Cord Injury
Seok-Hee Han, In Kyoung Cho, Joo Hwan Jung, Seong Ho Jang, Bum-Suk Lee
Ann Rehabil Med. 2019;43(1):54-61. Published online 2019 Feb 28 DOI: https://doi.org/10.5535/arm.2019.43.1.54
|
|
Citations to this article as recorded by
 Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications
Lahanya Guha, Hemant Kumar
Pharmaceutical Medicine.2023; 37(6): 463. CrossRef Management of the Devastated Female Urethra
Anne Shirley Hoselton, Paige Kuhlmann, Ramy Goueli
Current Bladder Dysfunction Reports.2023; 18(4): 293. CrossRef Bowel and Bladder Care in Patients With Spinal Cord Injury
Eren O. Kuris, Daniel Alsoof, Camilo Osorio, Alan H. Daniels
Journal of the American Academy of Orthopaedic Surgeons.2022; 30(6): 263. CrossRef Urological Care After Spinal Cord Injury
Gamal Ghoniem, Dena Moskowitz, Catherine Nguyen
Current Physical Medicine and Rehabilitation Reports.2022; 10(2): 89. CrossRef Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review
Yesim Akkoc
Spinal Cord.2022; 60(10): 854. CrossRef Urogenital dysfunction following neurotrauma
Udit Saraf, Anand Kumar A, Jalesh N. Panicker
Current Opinion in Neurology.2022; 35(6): 753. CrossRef
|